1,411 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Tomtom NV reports Q1 results https://seekingalpha.com/news/3257794-tomtom-nv-reports-q1-results?source=feed_news_all Apr 19, 2017 - Tomtom NV (OTCPK:TMOAF): Q1 EPS of €0.03Revenue of €213M (-1.8% Y/Y)Press Release
Allergan (AGN) Collaborates with Novartis to Treat NASH http://www.zacks.com/stock/news/256887/allergan-agn-collaborates-with-novartis-to-treat-nash?cid=CS-ZC-FT-256887 Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
Jolley Asset Management, LLC Buys Anheuser-Busch InBev SA/NV, Qualcomm, Gilead Sciences, Sells ... http://www.gurufocus.com/news/505789/jolley-asset-management-llc-buys-anheuserbusch-inbev-sanv-qualcomm-gilead-sciences-sells-harman-international-industries-csx-bank-of-americaoration Apr 18, 2017 - Jolley Asset Management, LLC Buys Anheuser-Busch InBev SA/NV, Qualcomm, Gilead Sciences, Sells Harman International Industries, CSX, Bank of Americaoration, Stocks: BUD,QCOM,GILD,APA,TEVA,XOM,GDX,IVZ,CF,HAR,VOO,CMI,, release date:Apr 18, 2017
Portland Global Advisors LLC Buys Abbott Laboratories, Mobileye NV, WisdomTree India Earnings ... http://www.gurufocus.com/news/505766/portland-global-advisors-llc-buys-abbott-laboratories-mobileye-nv-wisdomtree-india-earnings-fund-sells-st-jude-medical-express-scripts-holding-co-nextera-energy Apr 18, 2017 - Portland Global Advisors LLC Buys Abbott Laboratories, Mobileye NV, WisdomTree India Earnings Fund, Sells St Jude Medical, Express Scripts Holding Co, NextEra Energy, Stocks: ABT,MBLY,EPI,STJ,ESRX,NEE,ITT,, release date:Apr 18, 2017
Why the Ionis Spinoff Will Be a Win for Long-Term Investors https://www.fool.com/investing/2017/04/18/why-the-ionis-spinoff-will-be-a-win-for-long-term.aspx?source=iedfolrf0000001 Apr 18, 2017 - Ionis keeps doing what it's good at: developing new drugs and setting up future revenue streams
Novartis (NVS) Up 7.7% Since Earnings Report: Can It Continue? http://www.zacks.com/stock/news/256596/novartis-nvs-up-77-since-earnings-report-can-it-continue?cid=CS-ZC-FT-256596 Apr 18, 2017 - Novartis (NVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc. https://www.fool.com/investing/2017/04/13/heres-why-the-best-is-yet-to-come-for-ionis-pharma.aspx?source=iedfolrf0000001 Apr 13, 2017 - A pipeline of drugs has this biotech poised for further success.
SBM Offshore NV ADR declares $0.23 dividend https://seekingalpha.com/news/3257097-sbm-offshore-nv-adr-declares-0_23-dividend?source=feed_news_all Apr 13, 2017 - SBM Offshore NV ADR (OTCPK:SBFFY) declares $0.23/share annual dividend, 8.5% increase from prior dividend of $0.212.Forward yield 1.39%Payable May 12; for shareholders of record April 20; ex-div April
Why Juno Therapeutics' Stock Tumbled in the Past One Year http://www.zacks.com/stock/news/256376/why-juno-therapeutics-stock-tumbled-in-the-past-one-year?cid=CS-ZC-FT-256376 Apr 13, 2017 - Juno Therapeutics, Inc.'s (JUNO) stock has significantly underperformed Zacks classified Medical-Biomed/Genetics industry in the past one year.
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected http://www.zacks.com/stock/news/256374/intellipharmaceutics-ipci-q1-loss-narrower-than-expected?cid=CS-ZC-FT-256374 Apr 13, 2017 - IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss of 9 cents per share.
<<<Page 129>